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Background: While the majority of studies have focused on the association between sex hormones and dementia,
emerging evidence supports the role of other hormone signals in increasing dementia risk. However, due to the
lack of an integrated view on mechanistic interactions of hormone signaling pathways associated with dementia,
molecular mechanisms through which hormones contribute to the increased risk of dementia has remained
unclear and capacity of translating hormone signals to potential therapeutic and diagnostic applications in relation
to dementia has been undervalued.
Methods: Using an integrative knowledge- and data-driven approach, a global hormone interaction network in the
context of dementia was constructed, which was further filtered down to a model of convergent hormone
signaling pathways. This model was evaluated for its biological and clinical relevance through pathway recovery
test, evidence-based analysis, and biomarker-guided analysis. Translational validation of the model was performed
using the proposed novel mechanism discovery approach based on ‘serendipitous off-target effects’.
Results: Our results reveal the existence of a well-connected hormone interaction network underlying dementia.
Seven hormone signaling pathways converge at the core of the hormone interaction network, which are shown to
be mechanistically linked to the risk of dementia. Amongst these pathways, estrogen signaling pathway takes the
major part in the model and insulin signaling pathway is analyzed for its association to learning and memory
functions. Validation of the model through serendipitous off-target effects suggests that hormone signaling
pathways substantially contribute to the pathogenesis of dementia.
Conclusions: The integrated network model of hormone interactions underlying dementia may serve as an initial
translational platform for identifying potential therapeutic targets and candidate biomarkers for dementia-spectrum
disorders such as Alzheimer’s disease.
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Figure 1 Schematic representation of the methodology used for
construction and analysis of dementia-related hormonal network.
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The clinical hallmark of dementia-spectrum diseases in-
cluding Alzheimer’s disease (AD) and front temporal de-
mentia is the gradual memory loss and impairment of
other cognitive functions, which has been attributed to
the aggregation of amyloid fibrils, a process known as
amyloidogenesis [1-3]. However, recent findings indicate
that many peptide and protein hormones are stored in
secretory granules in the form of functional amyloid fi-
brils and such an amyloid-like structure is necessary for
their natural functioning as hormones [4].
Moreover, observational studies on the beneficial effect
of estrogen-based hormone therapy on cognitive impair-
ment have also reported conflicting results [5]. Indeed,
gender-specific risk profiles observed for dementia in eld-
erly men and women have drawn attention to the impact
that sex hormones, as risk factors, may have on progres-
sion from mild cognitive impairment (MCI) to dementia
[6,7]. The higher risk of AD and dementia incidence in
women has been linked to high serum levels of endogen-
ous estrogen [8] and it has been shown to be influenced by
hormone replacement therapy [9-13], although a better
cognitive performance after current hormone therapy was
dependent on the duration and type of treatment [14].
On the other hand, both basic and clinical research
findings have consistently shown influence of a range of
hormones on some cognitive functions in AD. For ex-
ample, high levels of leptin in blood have been associated
to a lower risk of AD [15] and leptin replacement therapy
has been suggested as a novel therapeutic strategy for
AD [16]. The loss of melatonin in cerebrospinal fluid has
been observed in patients with dementia of Alzheimer’s
suggesting that it may play a role in the pathogenesis of
AD [17-20]. A low thyroid hormone level has been
also associated with AD [21,22]; the administration
of thyroid hormone in AD model mice prevented cognitive
deficit and improved the neurological function [23]. In
Alzheimer’s disease, a greater cognitive impairment has
been found to be associated with lower CSF concentrations
of corticotropin-releasing hormone [24,25]. There is evi-
dence that growth hormone (GH) declines with advancing
age or in Alzheimer’s disease [26-28] and that daily treat-
ment of healthy older adults with GH improves the cogni-
tion independent of gender [29]. A recent study also shows
that GH can boost memory retention in rats [30].
There are several lines of evidence that point to the
role of insulin signaling in AD; e.g. insulin levels in the
CSF of AD patients is lower than healthy controls
[31,32], insulin receptor signaling is compromised in
AD neurons [33], and insulin resistance is associated with
reductions in cerebral glucose metabolic rate, which is a
risk factor for developing AD dementia [34]. Interestingly,
epidemiological findings indicate that type II diabetes
mellitus is linked to developing and exacerbating ADpathology [35,36] so that Alzheimer’s has been even
proposed by some authors to be ‘type III diabetes’ [37,38].
Similar neuroendocrine disturbances have been reported
for Huntington’s disease under which the thyrotropic,
somatotropic and gonadotropic axes are altered [39].
All the above-mentioned evidence, including inconsist-
ent results and disparate findings, suggests that there is a
gap between the knowledge obtained from basic research
and findings of clinical investigations on the association be-
tween hormones and cognition. Context-specific networks
of molecular interactions provide a relevant framework for
supporting translation of basic knowledge into clinically
relevant information through integrative modeling of dis-
ease mechanism. Current Alzheimer’s disease maps, in-
cluding the recent Alz Pathway model [40], lack the
focused representation of hormone signaling path-
ways. Therefore, this work describes the first attempt to
characterize the hormone/hormone-receptor interactions
relevant to dementia disorders under a unified framework
of the interconnected hormonal components.
Methods
Figure 1 summarizes the overall strategy used for this
study. It demonstrates a top-down integrative (knowledge-
and data-driven) approach to modeling hormone protein
interaction network.
Literature mining
Our retrieval system was composed of two software com-
ponents: the dictionary-based text-mining tool, ProMiner
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ProMiner software uses dictionaries for the recognition of
a variety of different terminologies including gene, protein,
disease, SNP, drug, etc. The SCAIView software deploys
the results from ProMiner annotations, ranks the extracted
genes/proteins based on relative entropy scoring function
(i.e. mutual information measure), and displays the named
entities by tagging them through the text. SCAIView aca-
demic version can be freely accessed at http://bishop.scai.
fraunhofer.de/scaiview/. PubMed abstracts were searched
for all instances of genes and proteins, which are men-
tioned in the context of ‘dementia’ as keyword (accessed
as of 08.02.2011). The retrieved entities were manually
checked for their true relevance to both hormones and
dementia in the context of their abstracts.
Network reconstruction and annotation
The results from text-mining were cross-checked with
the contents of the EndoNet database [43] and the con-
firmed entities were used as seed proteins in the BIANA
tool for reconstruction of the dementia-related hormonal
network (DHN) at level 2 [44]. The initial protein-protein
interaction network was constructed around the seed set.
In order to reduce the dimensionality and increase the
confidence, interactions that are only supported by the
yeast two-hybrid method were removed and those interac-
tions that are independently confirmed by two or more ex-
perimental methods were maintained. The network was
visualized and statistically analyzed in the Cytoscape and
Gephi environments [45,46]. G-lay clustering algorithm
was used for modularity analysis [47].
Pathways used for the recovery test
For the pathway recovery test, we obtained the following
expert-curated hormonal pathways, used them as gold
standard, and mapped them onto the network: growth
hormone pathway [48], insulin signaling pathway [48],
leptin signaling pathway [49], thyroid hormone signaling
[50], regulation of the estrogen receptor pathway [48],
corticotropin-releasing hormone pathway [51], and Mela-
tonin signaling pathway [52].
Statistical analysis
Gene set enrichment analysis was performed using the
Molecular Signature Database [53]. DAVID functional
annotation tool was used for annotation of differentially
expressed genes in the network [54].
Translational validation
For establishing the clinical relevance of the core DHN
model, knockout mouse phenotypes were retrieved from
MGI database [55]. For retrieval and extraction of puta-
tive biomarker information from the literature, bio-
marker terminology was used [56]. Pathway membershipfor each target was obtained from KEGG database [57]
and their association to disease was determined using
genetic association database [58]. Information on brain
tissue specificity of the targets was obtained from Tissue
Distribution Database [59] but the higher resolution in-
formation at the cell type level was retrieved from the
literaure using SCAIView search engine.
DrugBank was searched for the proteins of the core
DHN as targets of approved drugs [60]. Then PubMed
was searched for supporting evidence of positive off-
target effects of non-dementia drugs that showed poten-
tial implication of those drug-targets in improvement of
dementia.
Results
Enrichment of dementia-related proteins for hormone
signaling activity
Mining the knowledge space of the literature for proteins
that are shown to play a role in dementia resulted in a list
of 1960 entities, which were ranked based on their mutual
information (see Methods). Due to the fact that high-
dimensional information returned by retrieval systems in-
herits noise, the next step was to observe whether signals
of hormonal proteins could be detected in this large list of
entities. The gene set enrichment analysis (GSEA) of these
proteins revealed under-represented signatures of hormone
activities in pathway analysis as well as implicit but statisti-
cally significant presence of hormone-related regulatory
gene sets in GO biological process annotations (Additional
files 1 and 2, respectively). However, at the level of GO
molecular function, these signatures showed significant
over-representation for hormone activity, neuropeptide
hormones and hormone signaling pathways (Table 1).
The results of this observation led us to raise the hypoth-
esis that an endocrine interaction network may exist that
substantially contributes to the pathology of the dementia-
spectrum diseases. To investigate this hypothesis, we used
text-mining and knowledge discovery technologies to nar-
row down our search for retrieval and extraction of in-
stances of hormone proteins and their receptors, which are
cited in the literature (Medline abstracts) in relation to de-
mentia. The focused search resulted in retrieval of 1329
documents and 453 protein entities extracted from them.
Finally, 89 hormone/hormone-receptor entities were con-
firmed to play a role as hormone/hormone-receptor after
crosschecking the retrieved entities with the contents of
the EndoNet database as gold standard (see Methods). We
use this initial set of proteins (seed set) as prior knowledge
to build upon our integrative model.
Dementia-related hormone network (DHN) and its
biological relevance
The initial protein-protein interaction network comprises
of 6966 nodes (proteins) and 85997 edges (interactions)
Table 1 Analysis of the retrieved data based on enrichment for gene ontology, category of molecular function
Gene set name Description of annotation P-value
Amine receptor activity GO:0008227: Combining with a biogenic amine to initiate a change in cell activity. 3.61E-05
Hormone activity GO:0005179: The action characteristic of a hormone, any substance formed in very
small amounts in one specialized organ or group of cells and carried (sometimes
in the bloodstream) to another organ or group of cells in the same organism,
upon which it has a specific regulatory action.
1.46E-04
Copper ion binding GO:0005507: Interacting selectively with copper (Cu) ions. 3.40E-03
Neuropeptide hormone activity GO:0005184: The action characteristic of a neuropeptide hormone, any peptide
hormone that acts in the central nervous system. A neuropeptide is any of several
types of molecules found in brain tissue, composed of short chains of amino acids.
6.55E-03
Serotonin receptor activity GO:0004993: Combining with the biogenic amine serotonin, a neurotransmitter
and hormone found in vertebrates, invertebrates and plants, to initiate a change
in cell activity.
1.40E-02
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to 83998. 6515 nodes form a giant connected component
and the rest of 451 nodes are singletons without any
connection; thus, for simplicity, we only consider the
giant component for further analyses. Statistical analysis
of the giant component of DHN shows that its node de-
gree distribution could be fitted in the power law of the
form y = 1092.8 × -1.17 with an acceptable goodness of fit
(R-squared value = 0.856, Correlation = 0.996). This indi-
cates that the network is of biological nature [61].
The network clustering coefficient of 0.315 and immense
distribution of the clustering coefficients around the nodes
with more than 100 neighbours is suggestive of a modular
organization consisting of several interconnected func-
tional modules. The modularity analysis of the networkFigure 2 An overview of modules detected in DHN. 19 modules were d
network. (A) The largest module is enriched for regulation of transcription. (
hormone and hormone receptor signaling pathways. (C) The third module
containing 1312 nodes is enriched for protein translation and induction of arevealed four major modules whose functional annotation
using GSEA supports the notion of modular organization
underlying the network (Figure 2): the largest module
with 2037 nodes (Figure 2A) is significantly enriched
for regulation of transcription, the second module with
1540 interconnected proteins (Figure 2B) is significantly
involved in hormone and receptor signaling, the third
module with 1420 proteins (Figure 2C) is significantly an-
notated for GPCR signaling, and finally the fourth module
containing 1312 nodes (Figure 2D) is enriched for protein
translation and induction of apoptosis (Additional files 3
and 4). These findings are consistent with the fact that hor-
mone peptides are major ligands for GPCRs and through
cellular signaling cascades, they regulate the transcription
of target genes in the nucleus.etected in DHN out of which 4 modules represent ca. 97% of the
B) The second module with 1540 interconnected proteins representing
with 1420 proteins enriched for GPCR signaling. (D) The fourth module
poptosis.
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Both the biological relevance and the modularity were fur-
ther evaluated by mapping the Alzheimer’s disease pathway
from the KEGG database as well as hormone signaling
pathways from other resources (see Methods). Mapping
the Alzheimer’s disease pathway onto the network resulted
in the recovery of all the proteins and their corresponding
interactions in the pathway except for APH1A.
Regarding hormone signaling pathways, the number of
proteins involved in the actual signaling and the number
of mapped proteins for each signaling pathway is shown
in Table 2. For two pathways with 100% node recov-
ery, i.e. insulin signaling pathway and growth hormone
pathway, manual extraction of edges (interactions) from
BioCarta and mapping them onto the network yielded
76% edge recovery (16 out of 21) for the growth hormone
pathway and 90% edge recovery (19 out of 21) for the in-
sulin signaling pathway.
We also surveyed our network for the presence of hor-
mone receptors by comparing them to known hormone
receptors of genomic neuroendocrine hormones and
were able to identify them for majority of these hormones
(Additional file 5).
Hormonal convergence in DHN
After the completion of this individual pathway recovery
test, we aggregated all the elements of these seven path-
ways and mapped them onto the giant component of
DHN. The aim was to detect the core of DHN where
the majority of hormone cross talks occur. A subnetwork
of 73 nodes and 133 edges was formed, representing the
converged hormonal pathway interactions. Interestingly,
62 of these hormone peptides (ca. 86%) are densely
interconnected and form the core of DHN. Besides, their
interactions appeared to occur in different regions of the
normal brain after adding the context of brain region an-
notations to each edge using the work of Bossi and Lehner
(2009) (Figure 3) [62]. Analysis of these annotations showsTable 2 List of dementia-related hormone signaling
pathways that were recovered fully or partially in DHN
Hormone signaling
pathway







Estrogen receptor pathway 30 25 (83% recovery)
Insulin signaling pathway 21 21 (100% recovery)
Growth hormone pathway 27 27 (100% recovery)
Leptin signaling pathway 21 17 (80% recovery)
Thyroid signaling pathway 11 8 (72% recovery)
Melatonin signaling pathway 16 16 (100% recovery)
Corticotropin-releasing
hormone signaling pathway
17 16 (94% recovery)that the majority of the hormonal interactions occur in
prefrontal cortex (ca. 93%), hypothalamus (ca. 92%) and
cingulate cortex (ca. 90%), respectively (Additional file 6).
The finding that interactions of the converged network
mostly occur in prefrontal cortex and cingulate cortex is
consistent with the neuroanatomical distribution of neuro-
fibrillary tangles and plaques in the cerebral cortex of AD
patients [63]. Moreover, the relevance of this finding to
clinical attributes of the advanced AD pathology has been
shown in several studies (Prefrontal cortex: [64,65];
Cingulate cortex: [66]; Hypothalamus: [67,68]). For ex-
ample, it has been shown that prefrontal cortex, an im-
portant component for working memory, is the site of
hormonal effects on cognition including estrogen [69],
insulin [70], growth hormone [71], and thyroid hormone
[72]. Thus, collective dysregulation of these pathways in
prefrontal cortex of AD patients can lead to worsened
memory impairment.
As the pathway-wise color codings in the converged
hormonal network in Figure 3 indicates, a strong con-
vergence and close interplay of hormone signals can be
observed at the molecular level of the brain interactome.
The yellow nodes show the common membership of
proteins in two or more of these pathways and are
significantly enriched for Neurotrophin/Trk signaling
(GSEA p-value: 0e0, 14 genes in overlap), through which
a variety of signaling cascades are connected and signals
of neuronal development, survival as well as additional
higher-order signals such as learning and memory are
transmitted. The extended portion of estrogen signaling
pathway in the core interactome is also noted.
Linking hormone-dementia hypothesis to mechanistic
evidence
Apart from above in silico analyses, we provide more
solid support for the hormone-dementia hypothesis from
Alzheimer’s reference expression data set [73], which
has been processed and used for identification of a
perturbed protein hub network in Alzheimer’s disease by
Liang et al. (2012) [74]. The Alzheimer’s reference data
set provides carefully phenotyped expression data set for
six brain regions from late-onset AD patients (GSE5281)
and lends support to the hypothesis that most of the dif-
ferentially expressed genes in these six brain regions rep-
resent hub proteins in the hub network specific to
Alzheimer’s disease. We compared the core DHN with
the Alzheimer’s hub network derived from Alzheimer’s
reference expression data set and found 18 hormone sig-
naling proteins in the core DHN that overlap with the
hub genes differentially expressed in the hub network of
Alzheimer’s disease (Additional file 7). As Additional file 7
indicates, all hormone signaling pathways are perturbed in
different brain regions, with the largest overlap between
insulin and growth hormone signaling pathways.Among
Figure 3 Elements of the seven hormonal signaling pathways form the core connected component of the brain interactome
(normal state with all possible interactions). Pathway memberships are indicated by color codings; Green: estrogen signaling pathway;
Red: insulin signaling pathway; Light blue: leptin signaling pathway; Dark blue: melatonin signaling pathway; Gray: thyroid signaling
pathway; Brown: corticotropin-releasing hormone pathway. Yellow color indicates common membership to two or more pathways and
also embeds the elements of the growth hormone signaling pathway.
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hormone signaling pathways, namely estrogen signaling
pathway and insulin signaling pathway.
Translational validation of the core DHN
To our knowledge, except for hormone therapy with es-
trogen, there is no clinical trial describing the effect of
other hormones on cognition improvement. Hence, in
the absence of clinical trials, we propose a strategy for
translational validation of the core DHN by showing the
clinical relevance of the core DHN to dementia in the
first step and then linking molecular signatures -
through mouse model phenotypes - to their corresponding
clinical manifestations.
The clinical relevance of the core DHN to dementia
can be established through biomarker-guided analysis, inwhich information of putative molecular indicators of
dementia is retrieved and extracted from the literature
and further become enriched with pathway membership,
disease association and tissue/cell type specificity data
(Table 3). Of the proteins in the core DHN, four were
found in the literature to be reported as potential bio-
markers that show measurable activity under Alzheimer’s
condition. These four proteins represent four different hor-
monal signaling pathways, namely growth hormone path-
way (MAPK3), corticotropin-releasing hormone pathway
(NOS1), melatonin signaling pathway (CREB1)and insulin
pathway (JUN), whose measurable activities under AD
condition suggest their mechanistic involvement in the
pathology of AD dementia.
Next, we sought to investigate the translational
value of DHN by linking hormone proteins in DHN
Table 3 Clinical relevance of the core DHN to dementia through biomarker-guided analysis
Target candidate Pathway membership Disease association Biomarker type Brain tissue specificity Cell-type specificity
MAPK3 Alzheimer’s disease, Prion disease,
Type II diabetes mellitus, Insulin signaling
pathway, Long-term potentiation
Autism CSF increased levels AD (PMID: 22145083,
19625747), Phosphorylation (PMID: 19233276,
16920298, 17612901), Alterations in
lymphoblasts of AD patients (PMID: 19158936)








Diabetes Mellitus type II
Nitric oxide overproduction (PMID: 20804853),
nNOS signaling initiated in interneurons
(PMID: 16758165), Increased expression of
nNOS isoforms in astrocytes (PMID: 12384247)
Substantia nigra, Forebrain, cerebral
white matter, Limbic system
Astrocytes, Neurons
CREB1 Huntington's disease, Cholinergic synapse Alzheimer's disease Impaired CREB phosphorylation (PMID:22119240) Substantia nigra, Brain stem, Sub-
commissural organ, Brain ventricle,
Cerebral gray matter, Cerebral white
matter, Forebrain, limbic system
Hippocampal neurons,
Dendate gyrus
JUN GnRH signaling pathway, Neurotrophin
signaling pathway, MAPK signaling pathway
Cognitive performance Prolonged expression of c-Jun (PMID:8774439),
Increased immuno-reactivity (PMID:8313943)
Sub-commissural organ, Brain ventricle,
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Table 4 summarizes 19 knockout mouse models re-
presenting 6 hormonal signaling pathways with phe-
notypes related to the nervous system. It also includes
the ratio of knockout studies reporting an effect on the
nervous system to studies reporting no effect on the ner-
vous system.
To establish the bridge between the observed mouse
phenotypes and the clinical disease manifestation in hu-
man, we propose the novel concept of “mechanism dis-
covery through serendipitous off-target effects” based on
the secondary positive effect of approved drugs that
leads to unexpected and serendipitous clinical observa-
tions. Many approved drugs that are routinely used for
treatment of human diseases lead to manifestation of so-
called ‘hidden phenotypes’ due to binding to unknown
targets [75]. The revelation of hidden phenotypes points
to the fact that off-target effects sometimes result in
positive effects through novel mechanisms of action.
The most prominent example is the positive effect of Sil-
denafil on erectile dysfunction while the drug had been
originally developed against angina.
Here we have collected a number of drugs with
reported serendipitous effects on cognition that target
several proteins in the core DHN (Table 5). Interestingly,
all the off-targets of these drugs, when compared to the
knockouts in Table 4, correspond to a nervous system
phenotype in mice. Landscape illustration of the off-
target effects in the core DHN model in Figure 4 shows
that modulation of the estrogen signaling pathway by
four drugs was more likely to lead to the serendipitous
off-target effect on dementia and consequently, to im-
proved cognitive functions observed in patients treated
with these drugs.
To enlighten the usability of the DHN model, we
performed a more general analysis by systematically
searching for non-dementia drugs with targets of the
core DHN model and retrieving published studies
that support the positive, negative or neutral effect of
those drugs on cognition or memory or learning. This
analysis demonstrated that of 62 proteins in the core
DHN model, 21 (ca. 33%) have been already targeted
by at least one drug out of which 18 drugs targeting
13 proteins have shown positive effect, 3 drugs targeting 1
protein have demonstrated negative effect, and 39
drugs targeting 18 proteins have not been investigated
in relation to cognitive functions or have not been
reported in the literature to have any observed effect
on dementia. 21 proteins (ca. 33%) have been targeted
by experimental compounds and 20 proteins (ca. 32%)
have not been targeted by any drug or compound
(Additional file 8). These findings imply that hormone
signaling pathways present a promising target space
for drug discovery.Discussion
Integrative modeling approaches provide a suitable
medium for fusion of complementary data derived from
literature and experiments. Given the fact that molecu-
lar mechanism of disease risk factors is often unclear
and the exact mode of action of most approved drugs is
unknown in most cases, such models can be used to in-
terpret disease mechanism and to predict drug mode of
action. In particular, an integrative model allows for in-
ference of cross talks among components of the system,
guidance of analysis to the core pathological pathways,
and generation of further hypotheses on how risk fac-
tors or disease-modifying treatments at molecular level
lead to manifestation of positive or negative clinical ef-
fects. Accordingly, our in silico approach to modeling
hormone signaling pathways that underlie dementia
pathology provided several novel insights beyond what
is already known about hormone signaling pathways in
dementia, as follows.
The growing number of findings on the role of hor-
mone signaling pathways in regulation of cognition and
memory raises an immediate question: how these bits
and pieces of accumulating knowledge are being used to
explain the contribution of hormones to improvement
or exacerbation of dementia? The dementia-related hor-
monal network, presented in this paper, provided a first
unified picture of the hormonal component underlying
cognitive impairment. Convergence of genomic hormo-
nal pathways in the DHN model uncovered tight mo-
lecular interconnections and cross talks among hormone
signaling pathways and regulatory pathways of neural
growth, survival and differentiation. For instance, the ob-
served convergence of estrogen and neurotrophin signaling
pathways at the core of DHN has been shown to regulate
an array of cytoskeletal and growth-associated genes in
cerebral cortex, including tau microtubule associated pro-
tein, MAPT [76]. The implication of such hormone signals
in the pathology of dementia is supported by the evidence
that phosphorylation of MAPT, which leads to neurofibril-
lary tangle formation and ultimately neurodegeneration, is
regulated by the signaling effects of insulin and estradiol
[77,78]. Similarly, the regulatory influence of thyroid hor-
mone, melatonin, and corticotropin-raleasing factors on
hippocampal tau phosphorylation has been documented in
the literature [79-81].
The DHN model could guide the mechanism discov-
ery analysis to those signaling pathways that constitute
the core pathological processes. The modularity detected
in the network implies that hormone receptors and hor-
mone signals in concert with transcription factors may
play a significant part in the disease mechanism. The
molecular interconnection of insulin pathway to dementia
pathology - revealed by the DHN model– may provide a
mechanistic explanation for the previous epidemiological
Table 4 Knockout mouse phenotypes observed for several proteins in the core DHN model
Name Mutation category Observed effects on the nervous system Ratio of KO studies with CNS phenotypes
to studies without CNS phenotypesEstrogen signaling
Esr1tm1Ksk Targeted (knock-out) abnormal pituitary gland physiology 4:8 (50%)
abnormal hypothalamus morphology
abnormal innervation
Ncor2tm1Kjep Targeted (knock-out) abnormal cerebral cortex morphology 1:0 (100%)
abnormal neuron differentiation
Hdac2tm1.2Rdp Targeted (knock-out) abnormal hippocampus CA1 region morphology 1:3 (34%)
abnormal dentate gyrus morphology
abnormal hippocampus pyramidal cell morphology
enhanced long term potentiation
Ccnd1tm1Wbg Targeted (knock-out) absent Purkinje cell layer 1:3 (34%)
abnormal cerebellar granule layer
small cerebellum
Crebbptm1Sis Targeted (knock-out) abnormal forebrain morphology 3:4 (75%)
Insulin signaling
Juntm1Wag Targeted (knock-out) abnormal forebrain morphology 1:2 (50%)
Hras1tm1Grnt Targeted (knock-out) reduced long term potentiation 1:3 (34%)
Csnk2a1 Targeted (knock-out) abnormal telencephalon development 1:2 (50%)
Mapk3tm1Gpg Targeted (knock-out) reduced long term potentiation 2:2 (100%)
Leptin signaling pathway
Leprtm1.2Chua Targeted (knock-out) abnormal inhibitory postsynaptic currents 1:4 (25%)
Stat3tm1Aki Targeted (knock-out) abnormal motor neuron morphology 1:6 (17%)
abnormal neuron physiology
Hif1atm1.1Stom Targeted (knock-out) abnormal cerebrum morphology 4:7 (57%)
abnormal cerebral cortex morphology
loss of cortex neurons
abnormal occipital lobe morphology
abnormal temporal lobe morphology
loss of hippocampal neurons
Thyroid signaling pathway
Rxrbtm1Rev Targeted (knock-out) abnormal excitatory postsynaptic potential 2:3 (67%)
reduced long term potentiation
absent long term depression
Corticotropin-releasing pathway
Gnaqtm1Soff Targeted (knock-out) abnormal glutamate-mediated receptor currents 1:2 (50%)
absent long term depression
Braftm1.1Sva Targeted (knock-out) increased neuron apoptosis 3:3 (100%)
abnormal innervation
thin cerebral cortex
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Table 4 Knockout mouse phenotypes observed for several proteins in the core DHN model (Continued)
Nos1tm1Plh Targeted (knock-out) abnormal brain wave pattern 3:4 (75%)
abnormal long term potentiation
reduced long term potentiation
absent long term depression
decreased synaptic glutamate release
abnormal peripheral nervous system regeneration
Melatonin signaling pathway
Gnai1tm1Drs Targeted (knock-out) abnormal long term potentiation 1:1 (100%)
Plcb1tm1Hssh Targeted (knock-out) loss of hippocampal neurons 1:1 (100%)
Creb1tm1Gsc Targeted (knock-out) abnormal CNS synaptic transmission 1:2 (50%)
reduced long term potentiation
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resistance as risk factors to exacerbation of dementia e.g.
[82-84]. For instance, very recently, a 9-year prospective
study on 3069 elderly adults without dementia demon-
strated that patients who suffered diabetes had significantly
worse cognitive decline in comparison with those who
did not have the disease, suggesting the contribution of
diabetes mellitus severity to accelerated cognitive impair-
ment [85]. An interesting observation in our model is
the co-occurrence of diabetes-related proteins in the con-
vergent core of DHN. Indeed, three members of this sub-
network (i.e. MAPK1, INSR, SOCS3) belong to the Type II
diabetes mellitus pathway, which fall into the bigger insulinTable 5 Drugs with serendipitous off-target effects on cognit




Skin cancer Rapid reversal of cognition, social and
olfactory deficits
Tamoxifen Breast cancer Higher level of independence in
activities of daily life and decision
making; relationship of tamoxifen
with a lower prevalence of AD
Raloxifene Breast cancer Reduced risk of cognitive impairment
in postmenopausal women
Vorinostat Cutaneous T cell
lymphoma
(skin cancer)
Complete restoration of contextual
memory
Lovastatin Hyperlipidemia Reduction of Abeta formation and
slowing the progression of AD
Resveratrol Aging Promoting clearance of Abeta peptides
Sorafenib Renal cell carcinoma Reversal of memory impairment
Naloxone Opioid overdose Improvement of learning and memory
through enhancement of long-term
potentiationsignaling pathway together with SHC1 and ELK1 (Figure 3).
As was shown by pathway recovery analysis in Table 2, the
insulin signaling pathway is present in the network with
the highest number of nodes and edges amongst other sig-
naling pathways. The presence of MAPK1/ELK1/CREBBP
axis in the core subnetwork (see Figure 3) and its direct
crosstalk to the insulin pathway is consistent with experi-
mental observations that link insulin signaling and diabetes
risk to the regulation of learning and formation of long-
term memory [86-88].
We showed that the DHN model could have more
valuable implications beyond a sole portrait of networked





Mouse model of AD 22323736 RXRA
RXRB
Cross-sectional study of women
receiving tamoxifen
11005221 ESR1






Mutant APPswe/PS1dE9 mice 20010553 HDAC2
HDAC3
Double-blind randomized study on
human subjects
11900994 HDAC2
Various cell lines 16162502 CSNK2A1
Transgenic APPswe mouse model 20201822 BRAF
Aged rats with declined memory 14670637 CREB1
15805661
Figure 4 Schematic off-target landscape of 8 non-dementia drugs in the core DHN model.
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hancement of the DHN model with knockout phenotype
data and drug-target information. Genetically engineered
mouse models play an instrumental role in studying dis-
ease mechanism and translating preclinical studies to the
clinic [89]. Thus, the knockout phenotypes are good can-
didates for establishing the link between the molecular
mechanism and the disease clinical manifestation. One
clear observation from knockout phenotypes in Table 4 is
the prominent involvement of all hormone signaling
pathways in long term potentiation (LTP) beside other
biological processes. It is well known that long term po-
tentiation of synaptic transmission substantially contrib-
utes to memory formation [90] and that LTP inhibitors
also block memory and learning [91]. Hence, it can be
inferred from the model that probably pertubarion in
hormone signaling pathways may affect LTP adversely.
Interestingly, knockout models of three putative bio-
markers for dementia in Table 3, namely MAPK3, NOS1
and CREB1, show reduced LTP (see Table 4), which sup-
ports the notion that hormone signaling pathways are
part of the dementia pathology. It should be noted that
these proteins generally exert multiple functions in the
biology of nervous system by participating in different
signaling pathways and thus, the core DHN model de-
scribes their contribution to the hormone-mediated sig-
naling in the context of dementia.Since mouse knockout phenotypes alone might not be
sufficient to concretely conclude about the translational
value of our DHN model, introduction of the “serendip-
itous off-target effect” for linking DHN model to disease
mechanism demonstrated to provide further validation
for the DHN model. It was shown that inhibition of off-
targets belonging to hormone signaling pathways could
lead to improvement of memory and learning in human
or animal models. Therefore, the enhanced DHN model
can be used to predict novel targets out of off-targtes or
to identify disease-modifying targets and pathways that
partially regulate the pathology of disease.For example,
HDAC2 knockout mouse models show enhanced LTP,
which may indicate HDAC2 might be a potential thera-
peutic target; on the other hand, the clinical evidence is
provided by the off-target effect of Lovastatin on HDAC2:
originally designed against hypercholesterolemia, Lova-
statin was tested during a double-blind, randomized clin-
ical study on human subjects for its effect on progression
of Alzheimer’s disease through reduction of amyloid-beta
formation [92]. The study found that Lovastatin decreases
the risk of AD progression. Such an inference exemplifies
how the novel knowledge on the mechanism of drug effect
on disease-related risk factors can be derived from the en-
hanced integrative model of DHN.
Although DHN provides a unified integrative map of
possible hormone signaling mechanism in the context of
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network biology is that completeness of molecular net-
work maps is limited to data availability and validity.
The DHN model analyzed in this work may not cover
all the hormone pathways involved in the pathogenesis
of dementia but rather it focuses on the convergent hor-
mone action by the most prominent ones. Furthermore,
such models provide only a static picture and do not
capture the dynamic behaviour of the system. However,
context-specific modeling, as the first step, makes it pos-
sible to simulate disease-specific perturbations after in-
corporation of quantitative data from high-throughput
technologies. Such an integrative modeling approach
may prove valuable for prediction of potential biomarkers
due to the fact that hormones are able to cross the blood–
brain barrier by transmembrane diffusion or using trans-
porters and their brain levels reflect blood levels [93]. We
plan to keep the DHN model up to date –within the
boundaries of available resources –by implementing an
alert system that automatically collects new information
published on the role of hormone signaling in dementia
and enriches the model with the emerging knowledge. It is
anticipated that, with the availability of more data, the
resolution (i.e. specificity and sensitivity) of the model will
increase so that new versions of the model will support
translational scientists to make informed decisions.
Conclusions
The integrated hormone interaction model presented in
this study can be beneficial in correlating the information
of genes, proteins, signaling pathways and the clinical
manifestation of dementia in the context of endocrine sys-
tem. Such models have great potential to support the
process of identifying new targets and novel biomarkers
and help the pharmaceutical industry to increase the effi-
ciency of their pipeline.
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